To Top
0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z


The information contained in the Organizational Database (ODB) is provided for informational purposes only. There is no implied endorsement by NORD. NORD does not promote or endorse participation in any specific organization. The information is subject to change without notice. Every effort is made to ensure that the details for each entry are as current as possible.

Smith-Magenis Syndrome Foundation



Email Address

[email protected]


The Smith-Magenis Syndrome Foundation is an international, self-help organization dedicated to providing information and support to individuals with Smith-Magenis syndrome and their families. Smith-Magenis syndrome is an extremely rare congenital disorder in which chromosomal material is absent from a certain portion of the short arm (p) of chromosome 17 (interstitial deletion 17p11.2) due to a spontaneous (de novo) genetic change early in embryonic development. Affected individuals may have a variety of associated symptoms and physical abnormalities including characteristic malformations of the head and facial area; abnormalities of the fingers and hands; speech delays and an unusually deep, hoarse voice; hearing loss; and/or moderate to severe mental retardation. In addition, many affected children may demonstrate self-destructive behavior. Established in 1992, the Smith-Magenis Syndrome Foundation UK is committed to disseminating information concerning Smith-Magenis syndrome to affected families and healthcare professionals; promoting awareness of the disorder in the United Kingdom; and providing networking opportunities to affected families to enable them to exchange information, support, and resources.

Please Note

The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.

NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.